PABPC1L诱导IDO1促进托芬代谢和免疫抑制在细胞癌
Guannan Shu1,2, Minyu Chen1, Wuyuan Liao1
1Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China.
Cancer research
|February 21, 2024
概括
聚乙烯酸结合蛋白PABPC1L通过增强胺2,3-二氧化酶1 (IDO1) 来驱动细胞癌 (RCC) 的免疫逃避. 抑制PABPC1L可能会增强RCC患者的免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 细胞癌 (RCC) 呈现出显著的免疫抑制和抵抗.
- 了解免疫逃避机制对于改善RCC免疫检查点阻塞 (ICB) 疗效至关重要.
研究的目的:
- 为了研究聚乙烯酸结合蛋白PABPC1L在RCC免疫逃避中的作用.
- 确定PABPC1L作为增强RCC中的ICB的潜在治疗标.
主要方法:
- 在RCC组织中分析PABPC1L表达.
- 研究PABPC1L对氨酸二氧化酶1 (IDO1) 和JAK2-STAT1信号的调控作用.
- 评估PABPC1L损失对T细胞功能和患者衍生异种移植模型中的抗PD-1治疗反应的影响.
主要成果:
- 在RCC中PABPC1L被上调,与预后不佳和ICB耐药性相关.
- PABPC1L通过稳定JAK2mRNA来增强IDO1表达,导致T细胞功能障碍和Treg透.
- PABPC1L的损失降低了IDO1,改善了T细胞功能,并增加了对抗PD-1疗法的敏感性.
结论:
- 通过调节 IDO1 途径,PABPC1L 是RCC 免疫逃避的一个关键驱动因素.
- 针对PABPC1L提供了一种潜在的策略,以克服ICB抵抗并改善RCC的结果.
更多相关视频
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.6K
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.6K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K